All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

10

Reset

10 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • HL-1186Phase 36 trials

    Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN )

  • matched to PregabalinPhase 32 trials

    Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain

  • matched to SUZPhase 32 trials

    Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain

  • YJ001Phase 32 trials

    Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Diabetic Peripheral Neuropathic Pain (DPNP)

  • HSK16149Phase 31 trial

    Haisco Pharmaceutical Group Co., Ltd. · Central Neuropathic Pain

  • LY4065967Phase 23 trials

    Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee

  • matched to VX-993Phase 22 trials

    Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain

  • VX-993Phase 22 trials

    Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain

  • LY3848575Phase 21 trial

    Eli Lilly · Neuropathic Pain, Distal Sensory Polyneuropathy

  • VMD-3866Phase 21 trial

    VM Therapeutics LLC · Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.